ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2017
Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 3 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- Roles of the gut microbiome in weight management.Nature reviews. Microbiology · 2023Pooled it
- Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.Frontiers in endocrinology · 2020Pooled it
- Pooled it
- Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study.International journal of molecular sciences · 2025Trial
- Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial.Frontiers in endocrinology · 2025Trial
- Consumption of yacon flour and energy-restricted diet increased the relative abundance of intestinal bacteria in obese adults.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Trial
- Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2022Trial
- Effects of Konjaku Flour on the Gut Microbiota of Obese Patients.Frontiers in cellular and infection microbiology · 2022Trial
- Habitual Dietary Intake Affects the Altered Pattern of Gut Microbiome by Acarbose in Patients with Type 2 Diabetes.Nutrients · 2021Trial
- [A machine learning model based on initial gut microbiome data for predicting changes of Bifidobacterium after prebiotics consumption].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018Trial
- Article
- Acarbose redirects gut microbiome utilization of dietary carbohydrates to suppress anaphylaxis in mice.Nature microbiology · 2026Article
- A Novel Strain Bifidobacterium longum subsp. longum HN001 Ameliorates High-Fat Diet-Induced Obesity in Mice Through Microbiome-Associated Short-Chain Fatty Acids.Probiotics and antimicrobial proteins · 2026Article
- Gut Microbiota Diversity and Function in Adults With Type 2 Diabetes, Alzheimer's Disease, and Both Conditions.International journal of microbiology · 2026Article
- The Japanese gut microbiome: ecology, uniqueness, and impact on health and disease.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2026Review
- The Modulatory Effects ofInternational journal of endocrinology and metabolism · 2025Article
- Sucrose-preferring gut microbes prevent host obesity by producing exopolysaccharides.Nature communications · 2025Article
- The direct and indirect inhibition of proinflammatory adipose tissue macrophages by acarbose in diet-induced obesity.Cell reports. Medicine · 2025Article
- Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with Type 2 diabetes.Scientific reports · 2025Article
- Innovative Application of Fermented Red Bean Seeds in Constructing Foods with Increased Biological Activity.Foods (Basel, Switzerland) · 2025Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe α-glucosidase inhibitor acarbose is an efficacious medicine for the treatment and prevention of type 2 diabetes mellitus (T2DM). However, the response of gut microbiota to acarbose is important, as the microbiota may have a critical role in the development of metabolic diseases, and acarbose is metabolized exclusively within the gastrointestinal tract. We explored the changes in the proportion and diversity of gut microbiota before and after treatment with acarbose in patients with prediabetes.
methodsWe designed a randomized, double-blind, controlled crossover trial in which 52 Chinese patients with prediabetes by an oral glucose tolerance test (OGTT) with a BMI of 18-35 kg/m
resultsOf the 52 participants who entered the study, 40 (76.9%) completed the protocol. On the basis of the operational taxonomic unit (OTU) profiles, a total of 107 OTUs were significantly altered after acarbose treatment, with 76 (71%) assigned to the order of Clostridiales. Ruminococcaceae (15 OTUs) and Lachnospiraceae (22 OTUs) decreased in response to acarbose, and 48 OTUs increased by 12.8-fold, including Lactobacillaceae (8 of 9 belonging to Lactobacillus), Ruminococcaceae (6 of 11 belonging to Faecalibacterium), and Veillonellaceae (8 of 15 belonging to Dialister). At genera level, five flourished after treatment with acarbose, including Lactobacillus and Dialister, while Butyricicoccus, Phascolarctobacterium, and Ruminococcus were inhibited.
conclusionThis study suggests that the benefits of acarbose for T2DM may correlate with the selective modulation of the gut microbiota.
trial registrationChinese Clinical Trial Register number, ChiCTR-TTRCC-13004112.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.